Physician profile
Mary Cueva
NPI 1023008083
$863.03
in general payments reported to CMS, 2019-2025
12 companies · $237 in 2025
The $237 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $241 · 2020: $61.38 · 2021: $27.83 · 2022: $60.13 · 2023: $118 · 2024: $118 · 2025: $237.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $473.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $473.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $401.65 | 2019-2025 | Airsupra, Farxiga |
| Pfizer INC. | $103.34 | 2019-2024 | |
| Lilly USA, LLC | $100.74 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $61.95 | 2019-2025 | Wegovy |
| Glaxosmithkline, LLC. | $35.50 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $34.35 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $29.52 | 2019 | |
| Zyla Life Sciences, INC. | $27.91 | 2019 | |
| Phadia US INC. | $20.95 | 2024 | Immunocap |
| Astellas Pharma US INC | $20.54 | 2024 | Veozah |
| Idorsia Pharmaceuticals US INC | $13.33 | 2023 | Quviviq |
| Tactile Systems Technology INC | $13.25 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Cueva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.